January 17, 2019 | English | عربي
Add to Twitter
Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours
Company granted broad and exclusive patent rights for the use of an epigenetic biomarker as a diagnostic tool for cancer.

5-hydroxymethylcytosine (5hmC) epigenetic sequencing technology platform being used to develop a screening test for the detection of colorectal and other cancers using a standard blood draw.

Company announces the appointment of new Chief Executive, Dr Suman Shirodkar, to lead the advancement of its scientific programmes.